108 related articles for article (PubMed ID: 21397034)
1. BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase.
Cherdon C; Rolin S; Hanson J; Ooms A; de Leval L; Drion P; Michiels C; Pirotte B; Masereel B; Sakalihassan N; Defraigne JO; Dogné JM
Prostaglandins Other Lipid Mediat; 2011 Apr; 94(3-4):124-32. PubMed ID: 21397034
[TBL] [Abstract][Full Text] [Related]
2. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis.
Cayatte AJ; Du Y; Oliver-Krasinski J; Lavielle G; Verbeuren TJ; Cohen RA
Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1724-8. PubMed ID: 10894809
[TBL] [Abstract][Full Text] [Related]
3. A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice.
Cyrus T; Yao Y; Ding T; Dogné JM; Praticò D
Eur J Pharmacol; 2007 Apr; 561(1-3):105-11. PubMed ID: 17306791
[TBL] [Abstract][Full Text] [Related]
4. Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism.
Ghuysen A; Lambermont B; Dogné JM; Kolh P; Tchana-Sato V; Morimont P; Magis D; Hanson J; Segers P; D'Orio V
J Pharmacol Exp Ther; 2004 Sep; 310(3):964-72. PubMed ID: 15121765
[TBL] [Abstract][Full Text] [Related]
5. Thromboxane receptors antagonists and/or synthase inhibitors.
Davì G; Santilli F; Vazzana N
Handb Exp Pharmacol; 2012; (210):261-86. PubMed ID: 22918735
[TBL] [Abstract][Full Text] [Related]
6. The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-/- mice.
Jacob S; Laury-Kleintop L; Lanza-Jacoby S
J Surg Res; 2008 May; 146(1):135-42. PubMed ID: 17950326
[TBL] [Abstract][Full Text] [Related]
7. Effects of the dual TP receptor antagonist and thromboxane synthase inhibitor EV-077 on human endothelial and vascular smooth muscle cells.
Petri MH; Tellier C; Michiels C; Ellertsen I; Dogné JM; Bäck M
Biochem Biophys Res Commun; 2013 Nov; 441(2):393-8. PubMed ID: 24161392
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.
Egan KM; Wang M; Fries S; Lucitt MB; Zukas AM; Puré E; Lawson JA; FitzGerald GA
Circulation; 2005 Jan; 111(3):334-42. PubMed ID: 15655126
[TBL] [Abstract][Full Text] [Related]
9. Altered TP receptor function in isolated, perfused kidneys of nondiabetic and diabetic ApoE-deficient mice.
Michel F; Simonet S; Vayssettes-Courchay C; Bertin F; Sansilvestri-Morel P; Bernhardt F; Paysant J; Silvestre JS; Levy BI; Félétou M; Verbeuren TJ
Am J Physiol Renal Physiol; 2008 Jan; 294(1):F120-9. PubMed ID: 17942572
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
[TBL] [Abstract][Full Text] [Related]
11. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
Vezza R; Nenci GG; Gresele P
J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
[TBL] [Abstract][Full Text] [Related]
12. Role of hydrogen sulfide in the development of atherosclerotic lesions in apolipoprotein E knockout mice.
Wang Y; Zhao X; Jin H; Wei H; Li W; Bu D; Tang X; Ren Y; Tang C; Du J
Arterioscler Thromb Vasc Biol; 2009 Feb; 29(2):173-9. PubMed ID: 18988885
[TBL] [Abstract][Full Text] [Related]
13. The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus.
Zuccollo A; Shi C; Mastroianni R; Maitland-Toolan KA; Weisbrod RM; Zang M; Xu S; Jiang B; Oliver-Krasinski JM; Cayatte AJ; Corda S; Lavielle G; Verbeuren TJ; Cohen RA
Circulation; 2005 Nov; 112(19):3001-8. PubMed ID: 16260636
[TBL] [Abstract][Full Text] [Related]
14. BM-520, an original TXA2 modulator, inhibits the action of thromboxane A2 and 8-iso-prostaglandin F2alphain vitro and in vivo on human and rodent platelets, and aortic vascular smooth muscles from rodents.
Rolin S; Hanson J; Vastersaegher C; Cherdon C; Pratico D; Masereel B; Dogne JM
Prostaglandins Other Lipid Mediat; 2007 Aug; 84(1-2):14-23. PubMed ID: 17643884
[TBL] [Abstract][Full Text] [Related]
15. Long-term administration of 3-deazaadenosine does not alter progression of advanced atherosclerotic lesions in apolipoprotein E-deficient mice.
Preusch MR; Bea F; Yang SH; Kreuzer J; Isermann B; Pedal I; Rosenfeld ME; Katus HA; Blessing E
J Cardiovasc Pharmacol; 2007 Aug; 50(2):206-12. PubMed ID: 17703138
[TBL] [Abstract][Full Text] [Related]
16. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice.
Kobayashi T; Tahara Y; Matsumoto M; Iguchi M; Sano H; Murayama T; Arai H; Oida H; Yurugi-Kobayashi T; Yamashita JK; Katagiri H; Majima M; Yokode M; Kita T; Narumiya S
J Clin Invest; 2004 Sep; 114(6):784-94. PubMed ID: 15372102
[TBL] [Abstract][Full Text] [Related]
17. Additive anti-atherogenic effect of thromboxane receptor antagonism with 12/15lipoxygenase gene disruption in apolipoprotein E-deficient mice.
Tang L; Ding T; Praticò D
Atherosclerosis; 2008 Aug; 199(2):265-70. PubMed ID: 18206890
[TBL] [Abstract][Full Text] [Related]
18. Protocatechuic acid, a metabolite of anthocyanins, inhibits monocyte adhesion and reduces atherosclerosis in apolipoprotein E-deficient mice.
Wang D; Wei X; Yan X; Jin T; Ling W
J Agric Food Chem; 2010 Dec; 58(24):12722-8. PubMed ID: 21090717
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time.
Dogné JM; Hanson J; de Leval X; Kolh P; Tchana-Sato V; de Leval L; Rolin S; Ghuysen A; Segers P; Lambermont B; Masereel B; Pirotte B
J Pharmacol Exp Ther; 2004 May; 309(2):498-505. PubMed ID: 14742735
[TBL] [Abstract][Full Text] [Related]
20. [Effect of PMTG on atherosclerotic lesion formation and expression of ICAM-1 and VCAM-1 in ApoE-deficient mice].
Fang W; Zhang HX; Wang LY; Qin YW; Wu Y; Wang W; Liu B
Zhongguo Zhong Yao Za Zhi; 2007 Jul; 32(13):1320-3. PubMed ID: 17879736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
